{
    "nctId": "NCT06096545",
    "briefTitle": "Axillary Management After Neoadjuvant Chemotherapy",
    "officialTitle": "Axillary Management After Neoadjuvant Chemotherapy: May Axillary Biopsy Replace Sentinel Lymph Node Biopsy?",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Breast Neoplasms, Breast Cancer Female",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Prediction of axillary status after neoadjuvant chemotherapy without SLNB",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18-65 years-old female patients\n* Clinical stage T1-3 and biopsy-proven N1 breast cancer\n* Axillary nodal involvement\n* Volunteer to participate in to study\n\nExclusion Criteria:\n\n* A history of axillary surgery or SLNB, prior axillary excisional lymph node surgery,\n* N2-3 disease with a decision for initial axillary lymph node dissection (ALND),\n* Diagnosis of inflammatory breast cancer,\n* Presence of distant metastasis\n* Incomplete chemotherapy, pregnancy, and lactation\n* T4 tumors\n* Refusal to participate in to study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}